サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1552540

米国の女性医療の市場規模、シェア、動向分析レポート：用途別、年齢別、薬物別、セグメント別予測、2024～2030年

U.S. Women's Health Market Size, Share & Trends Analysis Report By Application (Contraceptives, Endometriosis & Uterine Fibroids), By Age (50 Years & Above, Others), By Drug (Prolia, XGEVA), And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 130 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.02円
米国の女性医療の市場規模、シェア、動向分析レポート：用途別、年齢別、薬物別、セグメント別予測、2024～2030年
出版日: 2024年08月01日
発行: Grand View Research
ページ情報: 英文 130 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の女性医療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の女性医療市場規模は2030年までに296億8,000万米ドルに達し、2024年から2030年までのCAGRは4.04％で拡大すると予測されています。

対象疾患の有病率の上昇が市場成長の主な促進要因です。高齢化と肥満の増加に伴い、変形性関節症の有病率は増加すると予測されています。女性のホルモンバランスの乱れを引き起こす主な要因には、食生活の変化、ストレス、不妊症の原因となるアルコールの摂取などがあります。排卵障害、多嚢胞性卵巣症候群（PCOS）、子宮内膜症は不妊の主な要因です。

家族計画サービスに対する公的資金の増加は、市場の成長をさらに促進しています。米国では、毎年妊娠の約45％が望まない妊娠と推定されています。避妊技術の進歩や避妊薬に対する研究開発費の増加にもかかわらず、米国における計画外妊娠の割合は数十年間変わっていないです。このため、現代的でより効果的な避妊法を容易に利用できない低所得層の経済的負担が増大しています。それゆえ、連邦政府と州政府は、家族計画サービスと最新の避妊具へのアクセスの改善に向けて積極的に取り組んでいます。例えば、米国政府は2019年、家族計画とリプロダクティブ・ヘルス開発のためにUNFPAに6億800万米ドルの資金を提供しました。

さらに、児童婚は低開発経済諸国や新興経済諸国で最も一般的であり、しばしば早期の計画外妊娠につながっています。また、避妊に対する意識が低いことも、問題の深刻さを増しています。ユニセフによると、児童婚は過去10年間で15％減少しました。しかし、米国の一部の州では18歳未満の結婚を認める法律があるため、米国ではこの数は長年減少していないです。しかし、児童婚とそれが女性医療に与える影響に対処するための取り組みが国内で行われており、それには、政策変更の提唱、女児の教育の促進、児童婚の悪影響に関する意識の向上、影響を受ける女児や女性への支援サービスの提供などが含まれます。

さらに、さまざまな治療薬の開発・製剤化に携わる主な企業は、新薬を開発し市場での競争力を維持するために、共同研究や提携に注力しています。例えば、2022年10月、ソレラ・ヘルス社は、女性医療問題のニーズに対応するため、女性医療ネットワーク向けの世界初のデジタルポイントソリューションの発売を発表しました。さらに、2022年11月には、セベラ・ファーマシューティカルズが完全に女性医療に特化した新部門の立ち上げを発表しました。

米国の女性医療市場レポートハイライト

  • 薬剤別では、2023年にProlia薬剤セグメントが最大の収益シェアを占め、副作用が極めて少ない薬剤として広く採用されていることから、予測期間中に最も速いCAGRで成長すると予測されます。
  • 用途別では、家族計画に対する意識の高まりにより、避妊薬セグメントは予測期間中に最も速いCAGRを示すと予想されます。
  • 年齢別では、子宮内膜症、ホルモン性不妊症、PCOSなどの不妊に関する懸念がこの年齢層で高まっているため、2023年にはその他の年齢層が米国の女性用医薬品業界を支配します。
  • 流通チャネル別では、病院薬局における女性用健康治療薬の在庫と入手可能性が高いことから、2023年には病院薬局セグメントが市場を独占しました。
  • 主要な市場参入企業は、その存在感を維持するため、製品の発売と地理的拡大に絶えず注力しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の女性医療市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • 米国の女性医療市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • 価格分析

第4章 米国の女性医療市場：用途別推定・動向分析

  • 市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 米国の女性医療市場展望：用途別
  • 2018年から2030年までの市場規模と予測および動向分析
    • ホルモン性不妊症
    • 避妊薬
    • 閉経後骨粗鬆症
    • 子宮内膜症と子宮筋腫
    • 閉経
    • 多嚢胞性卵巣症候群（PCOS）

第5章 米国の女性医療市場：薬剤別推定・動向分析

  • 市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 米国の女性医療市場展望：薬剤別
  • 2018年から2030年までの市場規模と予測および動向分析

第6章 米国の女性医療市場：年齢別推定・動向分析

  • 市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 米国の女性医療市場展望：年齢別
  • 2018年から2030年までの市場規模と予測および動向分析

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店およびチャネルパートナーのリスト
    • 主要顧客
    • 主企業の市場シェア分析、2023年
    • AbbVie, Inc.
    • Bayer AG
    • Merck &Co., Inc.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Agile Therapeutics
    • Amgen, Inc.
    • Apothecus Pharmaceutical Corp.
    • Eli Lilly and Company
    • Ferring BV
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Women's Health Market, by application, 2018 - 2030 (USD Million)
  • Table 3 U.S. Women's Health Market, by drug, 2018 - 2030 (USD Million)
  • Table 4 U.S. Women's Health Market, by age, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Women's Health Market: market outlook
  • Fig. 10 Women's health competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Women's Health Market driver impact
  • Fig. 16 U.S. Women's Health Market restraint impact
  • Fig. 17 U.S. Women's Health Market strategic initiatives analysis
  • Fig. 18 U.S. Women's Health Market: Application movement analysis
  • Fig. 19 U.S. Women's Health Market: Application outlook and key takeaways
  • Fig. 20 Hormonal infertility market estimates and forecast, 2018 - 2030
  • Fig. 21 Contraceptives estimates and forecast, 2018 - 2030
  • Fig. 22 Postmenopausal osteoporosis market estimates and forecast, 2018 - 2030
  • Fig. 23 Endometriosis & uterine fibroids estimates and forecast, 2018 - 2030
  • Fig. 24 Menopause market estimates and forecast, 2018 - 2030
  • Fig. 25 Polycystic ovary syndrome (PCOS) estimates and forecast, 2018 - 2030
  • Fig. 26 U.S. Women's Health Market: Drug movement analysis
  • Fig. 27 U.S. Women's Health Market: Drug outlook and key takeaways
  • Fig. 28 ACTONEL market estimates and forecast, 2018 - 2030
  • Fig. 29 YAZ, Yasmin, Yasminelle estimates and forecast, 2018 - 2030
  • Fig. 30 FORTEO market estimates and forecast, 2018 - 2030
  • Fig. 31 Minastrin 24 Fe estimates and forecast, 2018 - 2030
  • Fig. 32 Mirena market estimates and forecast, 2018 - 2030
  • Fig. 33 NuvaRing estimates and forecast, 2018 - 2030
  • Fig. 34 ORTHO TRI-CY LO market estimates and forecast, 2018 - 2030
  • Fig. 35 Premarin estimates and forecast, 2018 - 2030
  • Fig. 36 Prolia market estimates and forecast, 2018 - 2030
  • Fig. 37 Reclast/Aclasta estimates and forecast, 2018 - 2030
  • Fig. 38 XGEVA market estimates and forecast, 2018 - 2030
  • Fig. 39 Zometa estimates and forecast, 2018 - 2030
  • Fig. 40 Others estimates and forecast, 2018 - 2030
  • Fig. 41 U.S. Women's Health Market: Age movement Analysis
  • Fig. 42 U.S. Women's Health Market: Age outlook and key takeaways
  • Fig. 43 50 years and above market estimates and forecasts, 2018 - 2030
  • Fig. 44 Postmenopausal osteoporosis market estimates and forecasts,2018 - 2030
  • Fig. 45 Endometriosis & uterine fibroids market estimates and forecasts,2018 - 2030
  • Fig. 46 Menopause market estimates and forecasts,2018 - 2030
  • Fig. 47 Others market estimates and forecasts, 2018 - 2030
  • Fig. 48 Others market estimates and forecasts, 2018 - 2030
  • Fig. 49 Market share of key market players - U.S. Women's Health Market
目次
Product Code: GVR-4-68040-106-9

U.S. Women's Health Market Growth & Trends:

The U.S. women's health market size is expected to reach USD 29.68 billion by 2030, expanding at a CAGR of 4.04% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of target diseases is a key driver for the growth of the market. With aging and the increasing prevalence of obesity, the prevalence of osteoarthritis is anticipated to grow. Some of the major factors responsible for hormonal imbalance in women include changes in dietary habits, stress, and consumption of alcohol, which can cause fertility issues. Ovulation problems, polycystic ovarian syndrome (PCOS), and endometriosis are major factors responsible for infertility.

The rise in public funding for family planning services is further driving the market growth. In the U.S., approximately 45% of pregnancies are estimated to be unwanted every year. Despite advancements in contraceptive technology and increased R&D spending on contraceptives, the rate of unplanned pregnancies in the U.S. has remained unchanged for decades. This has increased the economic burden on low-income families that do not have easy access to modern and more effective methods of contraception. Hence, federal & state governments are actively working toward improving family planning services and access to modern contraceptives. For instance, in 2019, the U.S. government provided USD 608 million in funding to UNFPA for family planning & reproductive health development.

Moreover, child marriages are most common in underdeveloped and developing economies, often leading to early and unplanned pregnancies. There is a lack of awareness about contraceptives, which amplifies the severity of the problem. According to UNICEF, child marriages decreased by 15% in the past decade. However, the number has not decreased over the years in the U.S. because laws in certain U.S. states allow marriages before 18 years. However, efforts to address child marriage and its impact on women's health are being undertaken in the country, which involve advocating for policy changes, promoting girls' education, raising awareness about the negative consequences of child marriage, and providing support services for affected girls and women.

Furthermore, key players involved in developing and formulating various therapeutics are focusing on collaborations and partnerships to develop novel drugs and maintain their competitive position in the market. For instance, in October 2022, Solera Health announced the launch of first-of-its-kind digital point solutions for women's Health networks to address women's health issues needs. Moreover, in November 2022, Sebela Pharmaceuticals announced the launch of a new division fully dedicated to women's health.

U.S. Women's Health Market Report Highlights:

  • Based on drug, the Prolia drug segment held the largest revenue share in 2023 and is anticipated to grow at the fastest CAGR over the forecast period owing to the wide adoption of the drug with very less side effects
  • Based on application, the contraceptives segment is expected to showcase the fastest CAGR over the forecast period, owing to an increase in awareness about family planning
  • Based on age, the others age segment dominated the U.S. women's health industry in 2023, due to the rising concerns of fertility, such as endometriosis, hormonal infertility, and PCOS in this age group
  • Based on distribution channel, the hospital pharmacy segment dominated the market in 2023 due to the high stock and availability of women's health therapeutics in the hospital pharmacies
  • Key market players are constantly focusing on product launches and geographical expansion to maintain their presence

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Age
    • 1.2.3. Drug
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database.
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. Age outlook
    • 2.2.3. Drug outlook.
  • 2.3. Competitive Insights

Chapter 3. U.S. Women's Health Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of target diseases
      • 3.2.1.2. Increasing initiatives by government and various organizations
      • 3.2.1.3. Rising publicly funded family planning services
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiry of major drugs
      • 3.2.2.2. Lawsuits related to products.
      • 3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices.
  • 3.3. U.S. Women's Health Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. U.S. Women's Health Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Women's Health Market by Application Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Hormonal infertility
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Contraceptives
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Postmenopausal osteoporosis
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Endometriosis & uterine fibroids
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Menopause
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Polycystic ovary syndrome (PCOS)
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Women's Health Market: Drug Estimates & Trend Analysis

  • 5.1. Drug Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Women's Health Market by Drug Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. ACTONEL
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. YAZ, Yasmin, Yasminelle
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. FORTEO
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Minastrin 24 Fe
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Mirena
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. NuvaRing
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. ORTHO TRI-CY LO
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.8. Premarin
      • 5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.9. Prolia
      • 5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.10. Reclast/Aclasta
      • 5.4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.11. XGEVA
      • 5.4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.12. Zometa
      • 5.4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.13. Others
      • 5.4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Women's Health Market: Age Estimates & Trend Analysis

  • 6.1. Age Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Women's Health Market by Age Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. 50 years and above
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2. Postmenopausal osteoporosis
        • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Endometriosis & uterine fibroids
        • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.4. Menopause
        • 6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.5. Others
        • 6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Others
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. AbbVie, Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Bayer AG
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Merck & Co., Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Pfizer, Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Teva Pharmaceutical Industries Ltd.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Agile Therapeutics
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Amgen, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Apothecus Pharmaceutical Corp.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Eli Lilly and Company
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Ferring B.V.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives